newsfilter
← Latest News
GlobeNewswire·

Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates

Cash, cash equivalents and investments of $262.1 million as of September 30, 2022; cash runway expected to fund operations into mid-2024 SAN FRANCISCO and SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma